SCHEMBL3257968

SCHEMBL3257968

O=C1NC(=O)C(c2cc3ccccc3o2)=C1c1cc2ccccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 5/20 0.49
PRKCG P05129 5/20 0.49
PRKCB P05771 5/20 0.49
PRKCA P17252 5/20 0.49
PRKCH P24723 5/20 0.49
PRKCI P41743 5/20 0.49
PRKCE Q02156 5/20 0.49
PRKCQ Q04759 5/20 0.49
PRKCZ Q05513 5/20 0.49
PRKCD Q05655 5/20 0.49
PRKD1 Q15139 5/20 0.49
PRKACA P17612 2/20 0.49
PRKACG P22612 2/20 0.49
PRKACB P22694 2/20 0.49
KDR P35968 2/20 0.43
CHEK1 O14757 1/20 0.43
FLT3 P36888 1/20 0.43
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
MAOB P27338 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415921 0.84 PRKD3 (0.62) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL78989 0.84 PRKD3 (0.62) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3959789 0.82 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL927135 0.81 RAB9A (0.54) KDRCHEK1FLT3NPC1RAB9A
SCHEMBL31615194 0.77 NPC1 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3148480 0.77 NPC1 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3908537 0.74 PRKD3 (0.59) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL6417753 0.74 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL2430291 0.73 CHEK1 (0.61) KDRCHEK1FLT3NPC1RAB9A
SCHEMBL12424814 0.71 KDR (0.54) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285357-A1 COMPOSITIONS AND METHODS FOR TRANSDIFFERENTIATING CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-09-14 US disclosed
EP-4157264-A1 COMPOSITIONS AND METHODS FOR TRANSDIFFERENTIATING CELLS The Regents of the University of California (US) 2023-04-05 EP disclosed
EP-2125683-B1 3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS UNIV ILLINOIS (US) 2013-10-23 EP disclosed
US-8207216-B2 Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-06-26 US disclosed
US-20100004308-A1 Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS 2010-01-07 US disclosed
EP-2125683-A1 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS The Board of Trustees of the University of Illinois (US) 2009-12-02 EP disclosed
WO-2008077138-A1 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004308-A1 Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors GSK3B, GSK3A, GSKIP PRKD3 941/4885PRKCG 1803/4885PRKCB 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.